The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cell Line, 2002Generation of Transplantable Dopamine Neurons from Human Emryonic Stem Cells
The focal nature of neuronal loss suggests that cell replacement therapy may be suitable for Parkinson's disease. Indeed, transplanted fetal midbrain cells survive in some Parkinson's patients for...
-
The Role of Protein Degradation in Parkinson's Disease, 2002RNAi Screening and Analysis of Factors Influencing ER-Associated Degradation and Alpha-Synuclein Aggregation in C. elegans
Failure of proteins to adopt their proper structure is a common cause of cellular dysfunction. Quality control mechanisms within cells serve to promote accurate protein folding. Breakdown of these...
-
The Role of Protein Degradation in Parkinson's Disease, 2002Lentiviral Mediated Effect of Chaperones & Parkin in a Genetic Model of Parkinson's disease
The study of familial Parkinson disease indicates that the loss of nerve cells of a brain structure named the substantia nigra may be related to the accumulation of proteins aggregating within these...
-
The Role of Protein Degradation in Parkinson's Disease, 2002Regulation of Nurr1 Nuclear Receptor Transcriptional Activity by the Ubiquitin Proteasome System
Parkinson's disease (PD) is a neurodegenerative disease involving progressive and selective death of dopamine producing neurons located in the midbrain. Survival and normal activity of these neurons...
-
Cell Line, 2002Generation of Functional Dopamine Neurons of Human Origin for Grafting in Parkinson's Disease
The project will use multipotent neural stem cells as starting material. These cells, which reside in the central nervous system, will be isolated from the developing brains of five- to eight-week-old...
-
Fast Track, 2001Lentiviral Delivery of Neublastin to MPTP-Treated Pre-clinical models
Parkinson's disease (PD) results primarily from striatal dopamine (DA) insufficiency and degeneration of dopaminergic neurons within the substantia nigra pars compacta. The cause of PD still remains...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.